Oncolytics Biotech (TSE:ONC) Stock Price Passes Above 200-Day Moving Average – Time to Sell?

Oncolytics Biotech Inc. (TSE:ONC)’s share price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of C$14.90 and traded as high as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares.

Oncolytics Biotech Stock Down 1.3%

The company has a fifty day simple moving average of C$14.90 and a 200-day simple moving average of C$14.90. The company has a quick ratio of 8.86, a current ratio of 2.88 and a debt-to-equity ratio of 14.58. The firm has a market cap of C$1.50 billion, a P/E ratio of -40.27 and a beta of 0.80.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.